Allspring Global Investments Holdings LLC Sells 81,928 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Allspring Global Investments Holdings LLC cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 73.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,777 shares of the company's stock after selling 81,928 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.10% of Krystal Biotech worth $4,660,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. State Street Corp grew its holdings in shares of Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Geode Capital Management LLC grew its stake in Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after buying an additional 11,411 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after buying an additional 62,178 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Krystal Biotech by 9.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company's stock valued at $43,727,000 after buying an additional 19,777 shares in the last quarter. Finally, Braidwell LP lifted its holdings in shares of Krystal Biotech by 57.4% during the 3rd quarter. Braidwell LP now owns 168,691 shares of the company's stock worth $30,707,000 after acquiring an additional 61,512 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday. Chardan Capital boosted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday. Finally, HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $210.00.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 14.10% of the company's stock.

Krystal Biotech Price Performance

KRYS traded up $5.24 during trading on Friday, hitting $187.86. 293,600 shares of the stock traded hands, compared to its average volume of 260,850. The firm has a market capitalization of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84. Krystal Biotech, Inc. has a 12-month low of $107.50 and a 12-month high of $219.34. The firm has a 50-day moving average of $157.37 and a 200 day moving average of $175.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 earnings per share. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).